Hengrui Medicine (01276.HK): Rekascimab for Injection Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (01276.HK) announced that recently, Guangdong Hengrui Pharmaceuticals Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for Rekascimab for Injection, and will conduct clinical trials in the near future.